Table 1.
Patient demographics
| Study first author, year, reference | Patients (M:F) |
Groups (M:F) | Age, years, mean±SD | BMI (kg/m2)±SD | KL grade | Dropout rate (n) | Adverse events N (%) |
| Panda (2018)26 | 50; N/A | Curene 25 (N/A) Placebo 25 (N/A) |
Total: 54.16±8.40. Curene: 55.20±8.58. Placebo: 53.12±8.25 | 25.18±2.36 | Inclusion criteria of KL grade of 3 or 4 set; no breakdown provided | Curene: n=1 Placebo: n=3 |
Curene: n=2 (8%) Placebo: n=3 (12%) |
| Nakagawa (2014)27 | 41; (9:32) | Theracurcumin 18 (4:14) Placebo 23 (5:18) |
Total:68.7±7 Theracurcumin: 71.9±5.3 Placebo: 66.1±7.2 |
24.9±2.4 | Grade 1:0 Grade 2:33 Grade 3:8 Grade 4:0 | Theracurcumin: n=5 Placebo: n=2 |
None |
| Madhu (2013)28 | 120; (37:83) | Turmacin 30 (13:17) Placebo 30 (13:17) Glucosamine 30 (5:25) Glucosamine+Turmacin 30 (6:24) | Total: 57.09±9.41 Turmacin: 56.63±10.58 Glucosamine: 56.80±7.99 Turmacin+glucosamine: 58.17±9.30 |
27.67±4.30 | Inclusion criteria of KL grade of 2 or 3; no breakdown provided | Turmacin: n=1 Placebo: n=1 Glucosamine: n=2 Glucosamine+Turmacin: n=6 |
Turmacin: n=2 (6.7%) Placebo: n=2 (6.7%) Glucosamine: n=5 (16.7%) Turmacin+glucosamine: n=4 (14.3%) |
| Belcaro (2010)29 | 100; (51:49) | Meriva 50 (23:27) Control group 50 (28:22) | Total: 43.9±5.73 Meriva: 43.6±5.5 Control group: 44.2±6 | N/A | N/A | Meriva: n=5 Control group: n=6 |
None documented |
| Shep (2019)30 | 139; (93:46) | Curcumin (BCM-95) 70 (45:25) Control group 69 (48:21) |
Total: 52.62±3.99 Curcumin (BCM-95): 53.09±4.17 Control group: 52.14±3.76 |
N/A | N/A | Curcumin (BCM-95): n=4 Control group: n=6 |
Curcumin (BCM-95): n=9 (13%) Control group: n=26 (28%) |
| Panahi (2014)31 | 40; (9:31) | Curcuminoids 21 (5:16) Placebo 19 (4:15) |
Total: 57.44±8.83 Curcuminoids: 57.32±8.78 Control group: 57.57±9.05 |
29.22±3.88 | N/A | Curcuminoids: n=8 Placebo: n=5 | Curcuminoids: n=3 (14%) Placebo group: n=4 (21%) |
| Henrotin (2013)32 | 150; (28:113) | Flexoyfytol high dose 49 (10:39) Flexofytol low dose 47 (7:40) Placebo 45 (11:34) |
Total: 61.83±8.42 High dose Flexoyfytol: 60.9±9.78 Low dose Flexoyfytol: 61.4±7.49 Placebo: 63.3±7.69 |
29.73±5.08 | Grade 1: 0 Grade 2: 87 Grade 3: 53 Grade 4: 1 |
High dose Flexoyfytol: n=21 Low dose Flexoyfytol: n=17 Placebo: n=11 |
High dose Flexoyfytol: n=18 (37%) Low dose Flexoyfytol n=10 (21%) Placebo: n=6 (13%) |
| Kuptniratsaikul (2009)33 | 107; (21:86) | Curcumin extract 52 (11:41) Control group 55 (10:45) |
Total: 60.68±8.54 Curcumin extract: 61.4±8.7 Control group: 60.0±8.4 |
26.61±4.29 | N/A | Curcumin extract: n=7 Control group: n=9 | Curcumin extract: n=16 (33.3%) Control group: n=23 (44.2%) |
| Kuptniratsaikul (2014)34 | 367; (71:296) | Curcumin extract 171 (14:157) Control group 160 (21:139) |
Total: 60.60±6.85 Curcumin extract: 60.3±6.8 Control group: 60.9±6.9 |
26.54±3.84 | Grade 1: 42 Grade 2: 131 Grade 3: 102 Grade 4: 55 |
Curcumin extract: n=11 Control group: n=14 |
Curcumin extract: n=55 (32%) Control group: n=65 (40.6) |
| Srivastava (2016)35 | 60; (57:103) | Curcumin extract 78 (25:53) Control group 82 (32:50) |
Total: 50.25±8.34 Turmeric group: 50.23±8.08 Control group: 50.27±8.63 |
27.84±5.43 | Grade 1: 11 Grade 2: 30 Grade 3: 66 Grade 4: 53 |
Curcumin extract: n=12 Control group: n=15 | Curcumin extract: n=2 (2.5%) Placebo: n=4 (4.8%) |
BMI, body mass index; KL grade, Kellgren-Lawrence grade.